Broker Meets Biotech
September 2017
Dr. Rosalind Wilson
CEO
Disclaimer

• The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares in any jurisdiction.

• No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

• This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Factor Therapeutics Limited, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

• There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The photographs of clinical subjects used in this presentation are illustrative of medical conditions associated with potential applications of VF-001.

• Actual clinical results may vary from those shown.
Focus | Advanced wound care
---|---
Clinical Stage | Phase II US Pivotal EU
Issued Shares | 730,042,783
Options | 9.5m
Current Cash | AUD ~$10m
Symbol | FTT
Exchange | ASX
Research coverage | Morgans and Taylor Collison
Our Technology:
Targeting Growth Factors to the Wound

Our technology moves a wound toward a more normalised healing process by combining elements of two naturally-occurring substances:

Vitronectin
- Binds to collagen in the wound bed
- Provides a scaffold for skin cells to attach and move into the area to begin the healing process

Growth Factor (IGF-1)
- Signal to stimulate skin cells to move into the wound and multiply
VENOUS LEG ULCER
Preparing for End Of Phase 2 meeting (US) and return to CE Mark process (EU)

DIABETIC FOOT ULCER
Engaged with potential clinical collaborators
IND package available

OCULAR (PCED¹)
PCED is an orphan indication
Potential for rapid transition into clinical development

NEW OPPORTUNITIES
Monash collaboration in Harlequin Ichthyosis
Other orphan indications

1. Persistent corneal epithelial defect
What is a Venous Leg Ulcer?

A Venous Leg Ulcer (VLU) is a wound between the knee and ankle that is slow to heal because of problems with blood flow in the veins.

Risk factors for VLU include:
- Previous blood clot in the leg (DVT)
- Varicose veins
- Obesity
- Poor mobility e.g. age, arthritis, surgery
The Silent Epidemic of VLU – Major Commercial Opportunity

2 MILLION WORKING DAYS LOST ANNUALLY

VENOUS LEG ULCERS

600,000 NEW CASES PER YEAR

68% FEEL ISOLATION
FEAR
DEPRESSION

$2 BILLION IN LOST WAGES

73% PATIENTS SUFFER FROM DISTURBED SLEEP

12.5% PATIENTS WILL RETIRE EARLY

$3.5 BILLION ANNUAL COST TO US HEALTHCARE SYSTEM

MORE THAN FOUR RECURRENCES
A Potential Game-Changer

• VF001 is targeted to help patients whose ulcers do not heal with standard treatment
• Little cost-benefit for more expensive &/or invasive treatments
• VF001 is a cost-effective treatment that can be used in the community setting – a potential game changer
Prior clinical data supports Phase 2 trial design

- Early clinical trial – the VitroCARD study - conducted in 2012
- Wound size was significantly reduced after 12 weeks of treatment
Clinical Trial: Precision Medicine for VLUs

VF00102

1. Moisture dressings and compression bandaging

2. 24 sites at 7th July

168 patients at 26 planned sites

Moderately severe “Margolis 1” ulcers

All patients receive standard care during screening, treatment and follow-up

Screening
2 weeks

Treatment
12 weeks

Follow-up
12 weeks

Randomised to treatment with

- VF001 - low or high dose
- Matching placebo

Primary endpoint

- Reduction in ulcer size (% area)

Secondary endpoints

- % of patients with complete closure
- Time to ulcer closure
- Quality of Life
- Pain reduction

1. Moisture dressings and compression bandaging
2. 24 sites at 7th July
VF00102 Trial Status

- 280 patients pre-screened and 450 patient visits¹
- All sites actively seeking patients – high level of engagement
- Enrolment increasing steadily

- Pre-screening helping to focus on the population of interest
- High patient compliance with only one withdrawal
- Still targeting full enrolment this year

¹ At 7 July, 2017
VLU Value Inflection Points

Near-term catalysts

- Recruitment update – early October
- Targeting to finish recruitment in Q4

A successful Phase 2 outcome is a major inflection point

- Increases potential of early partnering deal
- Serves as a second pivotal study for potential CE Mark resubmission
- Enables go/no go decision for progression to Phase 3 pivotal studies
Experienced Management Team

Dr Rosalind Wilson, CEO
Dr Wilson’s career has spanned a variety of senior leadership and advisory roles, from small, innovation-led businesses, to global biopharma, including strategy and portfolio management roles at F.Hoffman-LaRoche (Roche Australia, UK and Switzerland), and Business Manager at NucleusX.

Mr Anthony Bishop, Project Director
Mr Bishop gained experience in a wide range of drug development and management roles. He previously worked for Quintiles in Australia and Asia in business development and project management roles, as well as leading drug development projects at CSL, Chakra Biotech and MerLion Pharmaceuticals.

Dr Gary Shooter, Director of R&D
Dr Gary Shooter is an experienced Protein Chemist and has a proven track record in the GMP manufacture and characterisation of protein-based therapeutics and products. Prior to joining the company, Dr Shooter was a Senior Research Fellow and Leader of the Tissue Repair and Regeneration Program at QUT.

Ms Saskia Jo, Director of Finance
Ms Jo has over 10 years' commercial experience in finance and compliance. She has been with the Company since 2011 and in additional to her financial management roles, serves as Company Secretary.

Mr Nigel Johnson, COO
Mr Johnson has broad experience in manufacturing, supply chain management, quality, R&D and regulatory affairs. He has been involved in delivering multiple regulated products from a blank sheet of paper into manufacturing, including leading the clinical translation of five recombinant proteins.

Mr Michael Larcom, Director of Quality
Mr Larcom is an experienced Quality Assurance (QA) professional in the pharmaceutical and medical device industries. He has key skills in pharmaceutical formulation and process development, internal and external audits (FDA, TGA and other third party audits), supplier relationship management, CAPA, validation, quality systems and start up.
Board of Directors

Dr Cherrell Hirst, Chair
Dr Hirst has had a distinguished clinical career in the detection and diagnosis of breast cancer and extensive and respected achievements as a director of multiple commercial, government and not-for-profit organisations. In addition she chairs the Advisory Board of the Institute of Molecular Biosciences at UQ.

Dr Christian Behrenbruch, NED
Dr Christian Behrenbruch has over 15 years of healthcare executive leadership experience, including roles as CEO (and executive director) at Mirada Solutions, CTI Molecular Imaging, and ImaginAb, Inc. Dr Behrenbruch is currently the CEO of Telix Pharmaceuticals Limited.

Mr Timothy Hughes, NED
Mr Timothy Hughes has over 30 years’ experience in senior roles in the investment management and investment banking industries, including roles as Chief Investment Officer at Rothschild Australia and Catholic Super. Mr Hughes currently sits on the Investment Advisory Panel of HESTA and on the Advisory Board of the Centre for Investor Education.

Mr John Michailidis, NED
Mr. Michailidis is currently the Managing Director for TEVA Australia/NZ and has spent the last 30 years of his career across a range of commercial pharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma).

Dr Robert Ryan
Dr. Ryan has more than 27 years of research, pharmaceutical and biotech experience, spanning the global development process across a wide verity of regulatory and clinical activities. Dr. Ryan is currently the President and CEO of Innova Therapeutics, and prior to this position held senior management roles at ScioDerm, Roche, Bristol-Myers Squibb (BMS) and Pfizer.
Investment Summary

- **Addressing a large unmet market need through precision medicine**
  - Global chronic wound care market is a multi-$Bn opportunity
  - We are treating a large, underserved group of patients who are easily identifiable and for whom VF001 is most likely to show maximum benefit

- **Superior product performance**
  - Wound healing for patients who have “failed” standard treatment; improvements in pain and Quality of Life

- **Validated platform technology**
  - Lead product VF001 has demonstrated potency and safety
  - Pipeline of follow-on products

- **Near-term catalysts and “blue sky” potential**
www.factor-therapeutics.com

For more information contact:

Dr. Rosalind Wilson
r.wilson@factor-therapeutics.com